- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07938567
Preeclampsia Screening Trial to Improve Outcomes (PRESTO)
Preeclampsia Screening Trial to Improve Outcomes: A Pre and Post Cohort Trial to Evaluate the Use of sFlt-1/PlGF Ratio in Women With Hypertensive Disorders of Pregnancy
The Pre-eclampsia Screening Trial to Improve Outcomes (PRESTO) research study aims to assess how clinicians use a blood test to guide care decisions in determining preeclampsia risk, with the overall aim of improving outcomes for both pregnant persons and their babies.
The study will evaluate whether a blood test can help doctors better identify pregnant patients with hypertensive disorders of pregnancy who are at risk of developing severe pre-eclampsia, which is a serious pregnancy condition that can affect organs such as the liver and kidneys and often leads to preterm delivery. The lab test measures two naturally occurring proteins in the blood that help estimate short-term risk for worsening disease. The goal is to determine whether providing this lab test result to clinicians can improve outcomes including safely prolong pregnancy, reduce unnecessary preterm deliveries, improve newborn outcomes, and optimize hospital care, without increasing complications for pregnant women or causing excess risks to the baby.
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
Participants will receive standard clinical care and will have a small blood sample drawn for the lab test. This study will have two phases: Phase A - the pre-phase and Phase B- the post-phase. The difference in the phases is whether test results are shared with doctors. Depending on when their hospital enters the study and which phase they are enrolled in, clinicians may or may not receive the test result, allowing researchers to compare outcomes before and after use of the test. Enrolled participants in both phases will have a blood draw, and data will be collected about their pregnancy and delivery.
Participants assigned to Phase A - the control phase, will not have their lab results shared with their doctor and will receive standard care. Participants assigned to Phase B - the intervention phase, will have their lab results shared with their doctor. Following phase A but before phase B, clinicians will receive education on the blood test and clinical management.
Participation lasts from hospital enrollment through delivery and discharge. Newborns will not undergo study procedures, but information will be collected from their medical records for them. The blood samples from the single lab draw will be stored temporarily for study analysis only and will not be banked for future unspecified research. No experimental drugs will be administered.
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Tae Stallworth
- Numero di telefono: 770-742-8942 |
- Email: tae.stallworth@emory.edu
Luoghi di studio
-
-
Georgia
-
Decatur, Georgia, Stati Uniti, 30033
- Emory Decatur Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Pregnant persons aged 18 years or older.
- Singleton pregnancy.
- Gestational age from 23 weeks 0 days through 33 weeks 6 days.
- Presentation to obstetric triage or hospitalization for a hypertensive disorder of pregnancy.
- Provision of signed informed consent (English- or Spanish-speaking).
Exclusion Criteria:
- Enrollment in another therapeutic interventional trial with a primary outcome of HDP
- Receipt of intravenous heparin during hospitalization.
- Planned delivery upon admission for HDP within 48 hours of admission (If a patient is admitted with no immediate plan for delivery, but then a delivery decision is made, patients will still be included and analyzed accordingly)
- Prior study enrollment during the current pregnancy.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Diagnostico
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione sequenziale
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Comparatore attivo: Blinded Test Results (Phase A)
Patients will be enrolled upon admission to the Labor & Delivery/Maternity or antepartum units. Triage units will be considered part of Labor & Delivery for this study. Management proceeds per local standard of care. Blood samples for sFlt-1/PlGF measurement will be collected and stored for later analysis; however, test results will remain blinded to clinicians and will not be available to guide clinical management during this phase. Biomarker measurements will be analyzed retrospectively for research purposes. |
Serum sFlt-1/PlGF biomarker, authorized by the U.S. Food and Drug Administration for use in pregnant patients with hypertensive disorders of pregnancy from 23+0 through 33+6 weeks of gestation.
Altri nomi:
|
|
Sperimentale: Real Time Results (Phase B)
Patients will be enrolled upon admission to the Labor & Delivery/Maternity or antepartum units. Triage units will be considered part of Labor & Delivery for this study. During the Intervention phase (post-implementation), results are reported in real time (within 24 hours) to treating clinicians. Management proceeds per the treating clinician, who has been educated to use the FDA-approved algorithm for the use of the test. |
Serum sFlt-1/PlGF biomarker, authorized by the U.S. Food and Drug Administration for use in pregnant patients with hypertensive disorders of pregnancy from 23+0 through 33+6 weeks of gestation.
Altri nomi:
sFlt-1/PlGF measurements will be available to clinicians in real time and may be incorporated into clinical management according to the FDA-approved algorithm |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Pregnancy latency
Lasso di tempo: At delivery (up to 40 weeks of gestation)
|
Time from admission to delivery |
At delivery (up to 40 weeks of gestation)
|
|
Participants with maternal adverse outcomes
Lasso di tempo: From enrollment until post-natal discharge (on average 10 days post-delivery)
|
The number of participants who experience one or more of the following maternal adverse events: cerebral hemorrhage, seizures (eclampsia), pulmonary edema, disseminated intravascular coagulation (DIC), new onset acute renal failure (creatinine > 1.4), peripartum cardiomyopathy, ischemic stroke, or HELLP syndrome [doubling of liver function test (LFT) and platelets count<100,000] or severe hypertension that required a parenteral infusion of a third-line antihypertensive. |
From enrollment until post-natal discharge (on average 10 days post-delivery)
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Number of participants who require hospital admission
Lasso di tempo: From enrollment up to 37 weeks of gestation
|
Number of participants who require hospital admission during study participation, collected form medical records. |
From enrollment up to 37 weeks of gestation
|
|
Number of participants with indicated delivery within 14 days of presentation
Lasso di tempo: Up to 14 days from enrollment
|
Participants who require delivery within 14 days of presentation |
Up to 14 days from enrollment
|
|
Number of participants who require transfer to tertiary care centers
Lasso di tempo: From enrollment until post-natal hospital discharge (on average 10 days post-delivery)
|
Participants who require transfer to tertiary care centers as documented in the medical records. |
From enrollment until post-natal hospital discharge (on average 10 days post-delivery)
|
|
Number of participants who received antenatal corticosteroid administration
Lasso di tempo: Between 24 weeks and 34 weeks of gestation
|
Participants who receive antenatal corticosteroid administration as documented in the medical records. |
Between 24 weeks and 34 weeks of gestation
|
|
Number of preterm births less than 37 weeks
Lasso di tempo: From enrollment up to 36 weeks and 6 days of pregnancy
|
Preterm births at <37 weeks' gestation between the pre-implementation and post-implementation periods. |
From enrollment up to 36 weeks and 6 days of pregnancy
|
|
Number of early preterm births
Lasso di tempo: From enrollment up to 31 weeks and 6 days of pregnancy
|
Early preterm births at <32 weeks' gestation between the pre-implementation and post-implementation periods. Analyses of preterm birth <32 weeks will be restricted to individuals enrolled before 32 weeks' gestation. |
From enrollment up to 31 weeks and 6 days of pregnancy
|
|
Composite Adverse Fetal/Neonatal Outcomes
Lasso di tempo: From maternal enrollment through 28 days after birth
|
Composite outcome defined as the occurrence of one or more of the following fetal or neonatal adverse events: fetal or neonatal death, low birth weight (<2500 g), respiratory distress syndrome (RDS), bronchopulmonary dysplasia, retinopathy of prematurity, necrotizing enterocolitis, or grade III/IV intraventricular hemorrhage. The proportion of participants experiencing the composite outcome will be compared between the intervention and control groups. |
From maternal enrollment through 28 days after birth
|
|
Length of hospital admission (mother's) of stay,
Lasso di tempo: From admission until post-natal hospital discharge (on average 10 days post-delivery)
|
Length of hospital admission, extracted from medical records |
From admission until post-natal hospital discharge (on average 10 days post-delivery)
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Suchitra Chandrasekaran, MD, Emory University
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 2026P000788
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Individual de-identified participant data may be made available upon reasonable request, subject to Sponsor review.
The specific data to be shared will be determined based on the Sponsor's review of the requested data and the nature of the request.
Periodo di condivisione IPD
No specific end date has been established.
Criteri di accesso alla condivisione IPD
Requests will be reviewed by the Research Team, and approved data will be shared through a method determined Requests will be reviewed by the Sponsor, and approved data will be shared through an appropriate method determined at the time of approval. Data will be shared with the Qualified researchers or organizations whose requests are approved by the Sponsor. Contingent upon the Sponsor's approved data request.
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .